Valuation: Zentalis Pharmaceuticals, Inc.

Market Cap 317M 279M 259M 238M 446M 30.59B 454M 3.08B 1.21B 14.99B 1.19B 1.16B 51.89B P/E 2026 *
-2.42x
P/E 2027 * -2.72x
Enterprise Value 105M 92.64M 86.09M 79.05M 148M 10.17B 151M 1.02B 401M 4.98B 395M 387M 17.24B EV / Sales 2026 *
-
EV / Sales 2027 * 6.46x
Free-Float
77.16%
Yield 2026 *
-
Yield 2027 * -
1 day-2.70%
1 week-5.25%
Current month-10.72%
1 month+17.66%
3 months+11.31%
6 months+47.28%
Current year+220.74%
1 week 4.16
Extreme 4.165
5.58
1 month 3.68
Extreme 3.675
5.58
Current year 1.32
Extreme 1.32
6.95
1 year 1.21
Extreme 1.212
6.95
3 years 1.01
Extreme 1.01
29.03
5 years 1.01
Extreme 1.01
87.19
10 years 1.01
Extreme 1.01
87.19
Manager TitleAgeSince
Chief Executive Officer 62 13/11/2024
Director of Finance/CFO - 13/11/2024
Chief Tech/Sci/R&D Officer 51 13/11/2024
Director TitleAgeSince
Chairman 61 16/05/2022
Director/Board Member 44 09/02/2021
Director/Board Member 59 12/09/2022
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Free

Director

57,100 0.0802%
16/06/26 Free

Director

57,100 0.0802%
16/06/26 Free

Chairman

57,100 0.0802%
Change 5-day change 1-year change 3-year change Capi.($)
-2.70%-5.25%+186.75%-83.47% 317M
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+7.22%+64.67%+63.56% 56.67B
-2.97%-2.44%-22.05%-17.74% 23.28B
-0.46%-0.50%+3.36%+407.21% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%-0.63%+29.60%-32.53% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.50%-0.56%+21.96%+181.21% 13.99B
Average -1.21%+0.16%+56.67%+147.30% 24.23B
Weighted average by Cap. -0.89%+1.46%+43.44%+135.27%

Financials

2026 *2027 *
Net sales - 19.28M 16.96M 15.76M 14.47M 27.16M 1.86B 27.62M 187M 73.37M 912M 72.36M 70.8M 3.16B
Net income -151M -133M -123M -113M -212M -14.56B -216M -1.46B -574M -7.14B -566M -554M -24.69B -155M -136M -127M -116M -218M -14.95B -222M -1.5B -589M -7.33B -581M -569M -25.36B
Net Debt -211M -186M -173M -159M -298M -20.42B -303M -2.05B -805M -10.01B -794M -777M -34.64B -192M -169M -157M -144M -271M -18.56B -275M -1.87B -732M -9.1B -721M -706M -31.48B
Logo Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Employees
106
Date Price Change Volume
24/07/26 $4.330 -2.70% 1,212,549
23/07/26 $4.450 -1.11% 992,448
22/07/26 $4.500 -10.18% 1,523,623
21/07/26 $5.010 0.00% 1,784,662
20/07/26 $5.010 -1.96% 1,784,011
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
4.450USD
Average target price
6.667USD
Spread / Average Target
+49.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZNTL Stock